Polymer conjugates as anticancer nanomedicines (original) (raw)

• Atkins, J. H. & Gershell, L. J. Selective anticancer drugs. Nature Rev. Cancer 1, 645–646 (2002).
  Article CAS Google Scholar
• Huang, P. S. & Oliff, A. Drug-targeting strategies in cancer therapy, Current Opin. Genet. Dev. 11, 104–110 (2001).
  Article CAS Google Scholar
• Moses, M. A., Brem, H. & Langer, R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4, 337–341 (2003).
  Article CAS PubMed Google Scholar
• Kamb, A. What's wrong with our cancer models? Nature Rev. Drug Discov. 4, 161–165 (2005).
  Article CAS Google Scholar
• Chabner, B. A. & Roberts, T. G. Timeline — chemotherapy and the war on cancer. Nature Rev. Cancer 5, 65–72 (2005).
  Article CAS Google Scholar
• Tsukagoshi, S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10. 8 mg depot). Outline of pre-clinical and clinical studies. Gan To Kagaku Ryoho 29, 1675–1687 (2002).
  PubMed Google Scholar
• Heyns, C. F., Simonin, M. P., Grosgurin, P., Schall, R. & Porchet, H. C. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 92, 226–231 (2003).
  Article CAS PubMed Google Scholar
• Brem, H. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008–1012 (1995).
  Article CAS PubMed Google Scholar
• Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 5, 79–88 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• US National Cancer Institute. NIH/NCI Cancer Nanotechnology Plan. US National Cancer Institute [online], (2004).
• European Science Foundation. European Science Foundation Forward Look on Nanomedicine. European Science Foundation [online], (2005).
• Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nature Rev. Cancer 5, 161–171 (2005).
  Article CAS Google Scholar
• Duncan, R. Targeting and intracellular delivery of drugs. in: Encyclopedia of Molecular Cell Biology and Molecular Medicine (ed. Meyers, R. A.) 163–204 (Wiley-VCH Verlag, GmbH & Co, Weinheim, Germany, 2005).
  Google Scholar
• Damle, N. K. & Frost, P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Phamacol. 3, 386–390 (2003).
  Article CAS Google Scholar
• Milenic, D. E., Brady, E. D. & Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nature Rev. Drug Disc. 3, 488–498 (2004).
  Article CAS Google Scholar
• Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750–763 (2002). Excellent description of ligands and technologies explored for tumour targeting. Includes information on antibodies, immunoliposomes, immuno-toxins and immuno–polymer conjugates.
  Article CAS Google Scholar
• Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Discov. 4, 145–160 (2005).
  Article CAS Google Scholar
• Brigger, I., Dubernet, C. & Couvreur, P. Nanoparticles in cancer therapy and diagnosis Adv. Drug Del. Rev. 54, 631–651 (2002).
  Article CAS Google Scholar
• Kattan, J. et al. Phase 1 clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10, 191–199 (1992).
  Article CAS PubMed Google Scholar
• O'Shaughnessy, J. A. et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metatastic breast cancer. Proc. San Antonio Breast Cancer Symposium 1070 (2004).
• Duncan, R. The dawning era of polymer therapeutics. Nature Rev. Drug Discov. 2, 347–360 (2003).
  Article CAS Google Scholar
• Duncan, R., Dimitrijevic, S. & Evagorou, E. G. The role of polymer conjugates in the diagnosis and treatment of cancer. S. T. P. Pharma Sciences 6, 237–263 (1996).
  Google Scholar
• Donaruma, L. G. Synthetic biologically active polymers. Progr. Polym. Sci. 4, 1–25 (1974).
  Article Google Scholar
• Seymour, L. W. Synthetic polymers with intrinsic anticancer activity. J. Bioact. Comp. Polymers 6, 178–216 (1991).
  Article CAS Google Scholar
• Regelson, W. & Parker, G. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest. 4, 29–42 (1986).
  Article CAS PubMed Google Scholar
• Duncan, R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3, 175–210 (1992).
  Article CAS PubMed Google Scholar
• Duncan, R. Polymer-anticancer drug conjugates. in Handbook of Anticancer Drug Development (eds Budman, D., Calvert, H. & Rowinsky, E.) 239–260 (Lippincott Williams & Wilkins, Baltimore, 2003). Overview describing the rationale for design and current clinical status of polymer–anticancer conjugates for the first time from the viewpoint of cancer-drug development.
  Google Scholar
• Kopecek, J., Kopeckova, P., Minko, T. & Lu, Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61–81 (2000).
  Article CAS PubMed Google Scholar
• Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nature Rev. Drug Discov. 2, 214–221 (2003).
  Article CAS Google Scholar
• Pasut, G., Guiotto, A. & Veronese, F. Protein, peptide and non-peptide drug PEGylation for therapeutic application. Expert Opin. Therap. Patents 14, 859–894 (2004).
  Article CAS Google Scholar
• Yokoyama, M. et al. Polymeric micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J. Cont Rel. 11, 269–278 (1990).
  Article CAS Google Scholar
• Pack, D. W., Hoffman, A. S., Pun, S. & Stayton, P. S. Design and development of polymers for gene delivery. Nature Rev. Drug Discov. 4, 581–593 (2005).
  Article CAS Google Scholar
• Wagner, E. & Kloeckner, J. Gene delivery using polymer therapeutics. Adv. Polymer Sci. 192, 135–174 (2005).
  Article CAS Google Scholar
• Kukowska-Latallo et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65, 5317–5324 (2005).
  Article CAS PubMed Google Scholar
• Duncan, R. & Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Del. Rev. 57, 2215–2237 (2005).
  Article CAS Google Scholar
• Maeda, H. & Konno, T. in Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (eds Maeda, H., Edo, K. & Ishida, N.) 227–267 (Springer Verlag, Berlin, 1997).
  Book Google Scholar
• Konno, T. & Maeda, H. in: Neoplasma of the liver (eds Okada, K. & Ishak, K. G.) 343–352 (New York, 1987).
  Book Google Scholar
• Iwai, K., Maeda, H. & Konno, T. Use of oily contrast medium for selective drug targeting to tumour: Enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2114–2121 (1984).
  Google Scholar
• Matsumura, Y. & Maeda, H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 6, 6387–6392 (1986). Milestone paper identifying for the first time the importance of passive tumour targeting through the EPR effect.
  Google Scholar
• Ishii, H. et al. A phase I study of hepatic arterial infusion chemotherapy with zinostatin stimalamer alone for hepatocellular carcinoma. Jap. J. Clin. Oncol. 33, 570–573 (2003).
  Article Google Scholar
• Taguchi, T. et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection Therapy with YM881. Gan To Kagaku Ryoho 18, 1665–1675 (1991).
  CAS PubMed Google Scholar
• Okusaka, T. et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 5, 276–283 (1998).
  Article Google Scholar
• Abe, S. & Otsuki, M. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Curr. Med. Chem. Anticancer Agents 2, 715–726 (2002).
  Article CAS PubMed Google Scholar
• Davis, F. F. The origin of pegnology. Adv. Drug Del. Rev. 54, 457–458 (2002). Important recent review that describes the pioneering research that opened the field of PEGylation.
  Article CAS Google Scholar
• Delgado, C., Francis, G. E. & Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249–304 (1992).
  CAS PubMed Google Scholar
• Fuertges, F. & Abuchowski, A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Cont. Rel. 11, 139–148 (1990).
  Article CAS Google Scholar
• Graham, M. L. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55, 1293–1302 (2003).
  Article CAS PubMed Google Scholar
• Ho, D. H. et al. Clinical pharmacology of polyethylene glycol-asparaginase. Drug Metab. Disposit. 14, 349–352 (1986). Landmark paper describing the first clinical studies involving PEGylated- L -asaparaginase.
  CAS Google Scholar
• Kurtzberg, J., Moore, J. O., Scudiery, D. & Franklin, A. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. Am. Assoc. Cancer Res. 29, 213 (1988).
  Google Scholar
• Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P. & Buchanan, G. R. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96, 1709–1715 (2000).
  CAS PubMed Google Scholar
• Cheng, P. N. et al. Pegylated recombinant human Arginase (rhArg-peg 5000Mw) has in vitro and in vivo anti-proliferative potential and apoptotic activities in human hepatocellular carcinoma (HCC). Proc. Am. Soc. Clin. Oncol. 96, abstract 3179 (2005).
  Article Google Scholar
• Delman, K. A. et al. Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma. Proc. Am. Soc. Clin. Oncol. 96, abstract 4139 (2005).
  Article Google Scholar
• Yang, Z. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 64, 6673–6678 (2004).
  Article CAS PubMed Google Scholar
• Katre, N. V., Knauf, M. J. & Laird, W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl Acad. Sci. USA 84, 1487–1491 (1987). The first development of a PEGylated cytokine.
  Article CAS PubMed PubMed Central Google Scholar
• Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343–346 (1990).
  CAS PubMed Google Scholar
• Zimmerman, R. J., Aukerman, S. L., Katre, N. V., Winkelhake, J. L. & Young, J. D. Schedule dependency of the antitumour activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumour models. Cancer Res. 49, 6521–6528 (1989).
  CAS PubMed Google Scholar
• Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S. & Asano, K. Pharmacokinetics of recombined human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51, 3710–3714 (1991).
  CAS PubMed Google Scholar
• Molineux, G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 10, 1235–1244 (2004). Excellent overview of the pioneering work that led to the design and development of PEG-G-CSF.
  Article CAS PubMed Google Scholar
• Holmes, F. A., et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 13, 903–909 (2002).
  Article CAS PubMed Google Scholar
• Heil, G. et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90, 4710–4718 (1997).
  CAS PubMed Google Scholar
• Reddy, K. R., Modi, M. W. & Pedder, S. Use of peginterferon α-2a (40KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Del. Rev. 54, 571–586 (2002).
  Article Google Scholar
• Wang, Y.-S. et al. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv. Drug Del. Rev. 54, 547–570 (2002).
  Article CAS Google Scholar
• Bukowski, R. et al. Pegylated interferon α-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol. 20, 3841–3849 (2002).
  Article CAS PubMed Google Scholar
• Huang, S. F. et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res. 62, 5720–5726 (2002).
  CAS PubMed Google Scholar
• Flaherty L., Heilbrun, L., Marsack, C. & Vaishampayan U. N. Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metastatic malignant melanoma. Proc. Am. Soc Clinical Oncol. 7562 (2005).
• Groves, M. D. et al. A phase II study of temozolomide plus pegylated interferon α-2b for recurrent anaplastic glioma and glioblastoma multiforme. Proc. Am. Soc Clinical Oncol. 1519 (2005).
• Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polymer Sci. Polymer Symp. 51, 135–153 (1975). Landmark paper that stimulated the field of polymer-anticancer conjugates.
  Article CAS Google Scholar
• Duncan, R. N-(2-Hydroxypropyl)methacrylamide copolymer conjugates. in: Polymeric Drug Delivery Systems (ed. Kwon, G. S.) 1–92 (Marcel Dekker, New York, 2005)
  Google Scholar
• O'Hare, K. B., Duncan, R., Strohalm, J., Ulbrich, K. and Kopeckova, P. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma. J. Drug Targeting 1, 217–229 (1993).
  Article CAS Google Scholar
• Low, P. S. and Antony, A. C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Del. Rev. 56, 1055–1058 (2004).
  Article CAS Google Scholar
• Brocchini, S. & Duncan, R. Pendent drugs, release from polymers. in Encyclopeadia of Controlled Drug Delivery (ed. Mathiowitz, E.) 786–816 (John Wiley & Sons, New York, 1999). Comprehensive review citing all of the studies involved in the pioneering research of many different polymer conjugates.
  Google Scholar
• Rihova, B. Biocompatibility of biomaterials: haematocompatibility, immunocompatibility, and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv. Drug Del. Rev. 21, 157–176 (1996).
  Article CAS Google Scholar
• Danauser-Reidl, S. et al. Phase-I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs 11, 187–195 (1993). First clinical evaluation of a dextran–drug conjugate.
  Article Google Scholar
• Kumazawa, E. & Ochi, Y. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models. Cancer Sci. 95, 168–175 (2004).
  Article CAS PubMed Google Scholar
• Takimoto, C. H. M. et al. A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. Proc. Am. Soc. Clin. Oncol. 22, 130 (abstr 522) (2003).
  Google Scholar
• Greenwald, R. B. et al. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Del. Rev. 55, 217–250 (2003).
  Article CAS Google Scholar
• Rowinsky, E. K. et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 21, 148–157, (2003).
  Article CAS PubMed Google Scholar
• Duncan, R., Pratten, M. K., Cable, H. C., Ringsdorf, H. & Lloyd, J. B. Effect of molecular size of 125I-labelled poly(vinylpyrrolidone) on its pinocytosis by rat visceral yolk sacs and rat peritoneal macrophages. Biochem. J. 196, 49–55 (1980).
  Article Google Scholar
• Seymour, L. W. et al. Effect of molecular weight (MW) of _N_-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mat. Res. 21, 1341–1358 (1987).
  Article CAS Google Scholar
• Seymour, L. W. et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31, 766–770 (1995).
  Article Google Scholar
• Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P. & Kopecek, J. Degradation of side-chains of _N_-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Reps 2, 1041–1046 (1983).
  Article Google Scholar
• Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P. and Kopecek, J. Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chains in poly [_N_-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 1997–2008 (1984). Experiments involving in vitro cell culture led to the discovery that thiol-dependent proteases were important targets for the design of peptide linkers.
  Article Google Scholar
• Duncan, R., Cable, H. C., Rejmanova, P., Kopecek, J. & Lloyd, J. B. Tyrosinamide residues enhance pinocytic capture of _N_-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys Acta 799, 1–8 (1984).
  Article CAS PubMed Google Scholar
• McCormick, L. A., Seymour, L. C. W., Duncan, R. & Kopecek, J. Interaction of a cationic _N_-(2-hydroxypropyl) methacrylamide copolymer with rat visceral yolk sacs culture in vitro and rat liver in vivo. J. Bioact. Compat. Polymers 1, 4–19 (1986).
  Article CAS Google Scholar
• Duncan, R., Kopecek, J., Rejmanova, P. & Lloyd, J. B. Targeting of _N_-(2-hydroxypropyl) methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta 755, 518–521 (1983).
  Article CAS PubMed Google Scholar
• Seymour, L. W. et al. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636–641 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Duncan, R. et al. Preclinical evaluation of polymer-bound doxorubicin. J. Cont. Rel. 19, 331–346 (1992). Landmark paper describing the preclinical and in vivo anti-tumour studies for HPMA copolymer-doxorubicin that paved the way for clinical testing of anticancer drug conjugates.
  Article CAS Google Scholar
• Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug–polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999). The first clinical study to evaluate a synthetic polymer–drug conjugate.
  CAS PubMed Google Scholar
• Thomson, A. H. et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer 81, 99–107 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Cassidy, J. PK1: Results of Phase I studies. Proc 5th Intl Symp on Polymer Therapeutics: From Laboratory to Clinical Practice, Cardiff, UK p 20 (2000).
• Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer bound doxorubicin. J. Clin. Oncol. 20, 1668–1676 (2002). The first clinical study describing a targeted polymer–anticancer drug conjugate.
  Article CAS PubMed Google Scholar
• Julyan, P. J. et al. Preliminary clinical study of the distribution of HPMA copolymer-doxorubicin bearing galactosamine. J. Cont. Rel. 57, 281–290 (1999).
  Article CAS Google Scholar
• Meerum Terwogt, J. M. et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315–323 (2001).
  Article CAS PubMed Google Scholar
• Schoemaker, N. E. et al. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Br. J. Cancer 87, 608–614 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Bissett, D. et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer, 91, 50–55 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wachters, F. M. et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br. J. Cancer 90, 2261–2267 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Sarapa, N. et al. Targeted delivery and preferential uptake in solid cancer of MAG-CPT, a polymer bound prodrug of camptothecin — a trial in patients undergoing surgery for colorectal carcinoma. Cancer Chemother. Pharmacol. 52 424–430 (2003).
  Article CAS PubMed Google Scholar
• Gianasi, E. et al. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Targeting 10, 549–556 (2002).
  Article CAS Google Scholar
• Rademaker-Lakhai, J. M. et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 10, 3386–3395 (2004).
  Article CAS PubMed Google Scholar
• Rice, J. R., Stewart, D. R. & Nowotnik, D. P. Enhanced antitumour activity of a new polymer-linked DACH-platinum complex. Proc. Am. Assoc. Cancer Res. 93, (2002).
• Rihova, B. et al. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Cont. Rel. 91, 1–16 (2003).
  Article CAS Google Scholar
• Li, C. et al. Complete regression well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 58, 2404–2409 (1998). Wallace, Li et al . were the pioneers who designed and established the basis for PGA–paclitaxel clinical development.
  CAS PubMed Google Scholar
• Singer, J. W. et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 519, 81–99 (2003).
  Article CAS PubMed Google Scholar
• Singer, J. W. et al. Paclitaxel poliglumex (XYOTAX; CT-2103) [XYOTAXTM]: an intracellularly targeted taxane. Anticancer Drugs 16, 243–254 (2005).
  Article CAS PubMed Google Scholar
• Singer, J. W. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J. Control. Rel. 109, 120–126 (2005).
  Article CAS Google Scholar
• Shaffer, S. A. et al. Proteolysis of XyotaxTM by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS. Eur. J. Cancer 38 (Suppl.), 428 (2002).
  Google Scholar
• Todd, R. et al. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)–paclitaxel conjugate. Proceedings of the AACR–NCI–EORTC 12th International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development, and Clinical Validation (2001).
  Google Scholar
• Langer, C. J. CT-2103: A novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer. 6 (Suppl. 2), S85–S88 (2004).
  Article CAS PubMed Google Scholar
• Langer, C. J. et al. Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study. Proc. Am. Soc. Clin. Oncol. 96, abstract LBA7011 (2005).
• Cell Therapeutics. Improving Outcomes in PS2 Patients: Results of the XYOTAX™ Phase III STELLAR Trials. 11th World Congress on Lung Cancer, Barcelona, Spain July (2005). Landmark paper showing gender differences in the activity of a polymer–drug conjugate designed for thiol-protease activation
• Socinski, M. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological sex differences: is gender-specific therapy warranted? Chemotherapy Foundation XXIII Symposium Innovative Cancer Therapy for Tomorrow, Mount Sinai November (2005).
  Google Scholar
• Kremer, M., Judd, J., Rifkin, B., Auszmann, J., Oursler, M. J. Estrogen modulation of osteoclast lysosomal-enzyme secretion. J. Cellular Biochem. 57, 271–279 (1995).
  Article CAS Google Scholar
• Bhatt, R. et al. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. 46, 190–193 (2003).
  Article CAS PubMed Google Scholar
• Springett, G. M. et al. Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. J. Clin. Oncol. 22 (Suppl.), S3127 (2004).
  Article Google Scholar
• Sat, Y. N. et al. Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer-doxorubicin (PK1) in human tumour xenografts. Proc. Am. Assoc. Cancer Res. 90, 41 (1999).
  Google Scholar
• St'astny, M., Strohalm, J., Plocova, D., Ulbrich, K., Rihova, B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 35, 459–466 (1999).
  Article CAS PubMed Google Scholar
• Malugin, A., Kopeckova, P. & Kopecek J. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian cancer cells by a Fas-independent pathway. J. Cont. Rel. 91, 254 (2003).
  Google Scholar
• Duncan, R. et al. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Cont. Rel. 16, 121–136 (1991).
  Article CAS Google Scholar
• Duncan, R. et al. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers, 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Cont. Rel. 10, 51–63 (1989).
  Article CAS Google Scholar
• Gianasi, E. et al. HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35, 994–1002 (1999).
  Article CAS PubMed Google Scholar
• Minko, T., Kopeckova, P. & Kopecek, J. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin. Macromol. Symp. 172, 35–37 (2001).
  Article CAS Google Scholar
• Kovar, L. et al. The effect of HPMA copolymer-bound doxorubicin conjugates on the expression of genes involved in apoptosis signaling. J. Cont. Rel. 91, 247–248 (2003).
  Google Scholar
• Rihova, B. et al. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Cont. Rel. 78, 97–114 (2002).
  Article CAS Google Scholar
• Rihova, B. et al. Drug-HPMA-HuIg conjugates effective against human solid cancer. Adv. Expt Med. Biol. 519, 125–143 (2003).
  Article CAS Google Scholar
• Nemunaitis, J. J. et al. Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): preliminary data. Proc. Am. Soc. Clin. Oncol. 96, Abstract 7230 (2005).
  Article Google Scholar
• Markman, M. Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103. J. Exp. Ther. Oncol. 4, 131–136 (2004).
  CAS PubMed Google Scholar
• Sabbatini, P. et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 22, 4523–4531 (2004)
  Article CAS PubMed Google Scholar
• Herzog, T., Barret, R. J., Edwards, R. & Oldham, F. B. Phase II study of paclitaxel poliglumex (PPX) /carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma. Proc. Am. Soc. Clin. Oncol. 96, Abstract 5012 (2005).
• Li, C. et al. Tumour irradiation enhances the tumour-specific distribution of poly(L-glutamic)-conjugates paclitaxel and its antitumour efficacy. Clinical Cancer Res. 6, 2829–2834 (2000)
  CAS Google Scholar
• Dipetrillo, T. A. et al. Paclitaxel poliglumex (PPX) and concurrent radiation for treatment of patient s with esophageal or gastric cancer: a dose-ranging study. Proc. Am. Soc. Clin. Oncol. 96, abstract 4065 (2005).
• Krinick, N. L. et al. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed. 5, 303–324 (1994).
  Article CAS PubMed Google Scholar
• Shiah, J.-G. et al. Combination chemotherapy and photodynamic therapy of targetable _N_-2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e6-OV-TL16 antibody immunoconjugates. J. Control. Rel. 74, 249–253 (2001).
  Article CAS Google Scholar
• Vicent, M. J., Greco, F., Nicholson, R. I. & Duncan, R. Polymer-drug conjugates as a novel combination therapy for the treatment of hormone-dependent cancers. Angew. Chem. Int. Ed. 44, 2–6 (2005).
  Article CAS Google Scholar
• Duncan, R., Vicent, M. J., Greco, F. & Nicholson, R. I. Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocrine-Rel. Cancer 12 (Suppl. 1), S189–S199 (2005)
  Article CAS Google Scholar
• Greco, F, Vicent, M. J., Penning, N. A., Nicolson, R. I. & Duncan, R. HPMA-copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J. Drug Targeting 13, 459–470 (2005).
  Article CAS Google Scholar
• Sawhney, R., Brescia, F., Keane, T., Clarke, H. & Chaudhary, U. B. Phase II trial of pegylated Interferon α-2b, GM-CSF, and thalidomide in metastatic progressive renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 96, abstract 4800 (2005).
• Unger, C. et al. Phase I dose escalating study of PEG-PGA and DON: A new amino acid depleting anti cancer drug approach. Proc. Am. Soc. Clin. Oncol. abstract 3130 (2005).
• Fang, H., Sawa, T., Akaike, T. & Maeda, H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 62, 3138–3143 (2002).
  CAS PubMed Google Scholar
• Satchi, R., Connors, T. A. & Duncan, R. PDEPT: Polymer directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070–1076 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Satchi-Fainaro, R., Hailu, H., Davies, J. W., Summerford, C. & Duncan, R. PDEPT: Polymer directed enzyme prodrug therapy: II. HPMA copolymer-β-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconj. Chem. 14, 797–804 (2003).
  Article CAS Google Scholar
• Satchi-Fainaro, R. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Med. 10, 225–261 (2004). Landmark paper describing the first polymer anti-angiogenic conjugate.
  Article CAS Google Scholar
• Satchi-Fainaro, R. et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate. Cancer Cell 7, 251–261 (2005).
  Article CAS PubMed Google Scholar
• Satchi-Fainaro, R. & Duncan, R. (Eds) Polymer therapeutics I. Adv. Polymer. Sci. 192, 1–204 (2005).
  Google Scholar
• Satchi-Fainaro, R. and Duncan R. (Eds.) Polymer therapeutics II. Adv. Polymer Sci. 193, 1–228 (2006).
  Article CAS Google Scholar
• Malik, N., Evagorou, E. G. & Duncan, R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10, 767–776 (1999).
  Article CAS PubMed Google Scholar
• Baker, J. R. et al. The synthesis and testing of anticancer therapeutic nanodevices. Biomed. Microdevices 3, 61–69 (2001).
  Article CAS Google Scholar
• Gillies, E. R. and Frechet, J. M. Dendrimers and dendritic polymers in drug delivery, Drug Discov. Today 10, 35–43 (2005).
  Article CAS PubMed Google Scholar
• Kochendoerfer, G. G. et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299, 884–887 (2003).
  Article CAS PubMed Google Scholar
• Shibata, H. et al. Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window. Clin. Cancer Res. 15, 8293–8300 (2004).
  Article Google Scholar
• Zhang, N., Khawli, L. A., Hu, P. & Epstein, A. L. The generation of a novel Rituximab Polymer which leads to CD20 hyper-crosslinking-induced apoptosis in non-hodgkin's Lymphomas. Proc. Am. Assoc. Cancer Res. 96, abstract 6144 (2005).
• Dharap, S. S. et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl Acad. Sci. USA 102, 12962–12967 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kataoka, K. et al. Block copolymer micelles as vehicles for drug delivery. J. Cont. Rel. 24, 119–132 (1993)
  Article CAS Google Scholar
• Bae, Y. et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconj. Chem. 16, 122–130, (2005).
  Article CAS Google Scholar
• Danson, S. et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90, 2085–2091 (2004). The first clinical studies using a polymeric micelle.
  Article CAS PubMed PubMed Central Google Scholar
• Washart, M. L. et al. Phase I dose escalation study of a polymeric micellar formulation of paclitaxel in patients (pts) with refractory non-hematologic cancer. Proc. Am. Soc. Clin. Oncol 96, abstract 2088 (2005).
• De Duve, C. et al. Lysosomotropic agents. Biochem. Pharmacol. 23, 2495–2531 (1974).
  Article CAS PubMed Google Scholar
• Ulbrich, K. & Subr, V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. 23, 1023–1050 (2004).
  Article CAS Google Scholar
• Lloyd, J. B. The lysosome/endosome membrane: a barrier to polymer-based drug delivery. Macromol. Symp. 172, 29–34 (2001).
  Article CAS Google Scholar
• Minko, T., Kopeckova, P., Pozharov, V. & Kopecek, J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Cont. Rel. 54, 223–233 (1998).
  Article CAS Google Scholar